FY2026 EPS Estimates for Exelixis Cut by Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL) – Equities researchers at Leerink Partnrs decreased their FY2026 earnings estimates for Exelixis in a report released on Tuesday, October 21st. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will post earnings per share of $2.35 for the year, down from their previous forecast of $2.75. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share.

Other analysts also recently issued research reports about the stock. Stifel Nicolaus raised their price target on shares of Exelixis from $38.00 to $41.00 and gave the stock a “hold” rating in a research report on Tuesday, July 29th. Truist Financial decreased their price target on shares of Exelixis from $56.00 to $49.00 and set a “buy” rating for the company in a research report on Tuesday, July 29th. Wells Fargo & Company decreased their price target on shares of Exelixis from $36.00 to $30.00 and set an “equal weight” rating for the company in a research report on Tuesday. Citigroup reissued a “market outperform” rating on shares of Exelixis in a research report on Tuesday. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $45.00 price target on shares of Exelixis in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $44.53.

Exelixis Stock Down 0.1%

Shares of NASDAQ:EXEL opened at $36.08 on Thursday. Exelixis has a 52-week low of $27.86 and a 52-week high of $49.62. The company has a 50 day moving average of $38.68 and a two-hundred day moving average of $39.99. The company has a market capitalization of $9.71 billion, a price-to-earnings ratio of 17.35, a price-to-earnings-growth ratio of 0.72 and a beta of 0.38.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. During the same quarter last year, the company earned $0.84 earnings per share. Exelixis’s revenue for the quarter was down 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Exelixis

A number of hedge funds have recently added to or reduced their stakes in EXEL. Hemington Wealth Management lifted its stake in Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 522 shares during the last quarter. Byrne Asset Management LLC lifted its stake in Exelixis by 129.0% in the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 400 shares during the last quarter. Luminist Capital LLC lifted its stake in Exelixis by 2,740.0% in the second quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 685 shares during the last quarter. Family Legacy Financial Solutions LLC bought a new stake in Exelixis in the second quarter valued at $33,000. Finally, Bartlett & CO. Wealth Management LLC bought a new stake in Exelixis in the first quarter valued at $37,000. 85.27% of the stock is currently owned by institutional investors.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.